Elevated Treasury yields near 5.3%—their highest level since 2002—combined with the Federal Reserve’s September 2026 rate hike and persistent inflation concerns have tempered IPO momentum in the final months of the year. These factors have pressured valuations and prompted postponements among larger AI-related deals, even as smaller biotech offerings such as TRexBio and City Therapeutics priced successfully in mid-October. Year-to-date U.S. equity issuance has already set records exceeding $146 billion, driven by AI capital expenditure and resilient equity demand, though Q3 saw softer deal flow excluding mega-transactions. Anthropic’s targeted November listing and a deep pipeline of filings suggest selective activity could persist through year-end, while OpenAI eyes 2027. The next FOMC decision and hyperscaler earnings represent key near-term catalysts for sentiment.